SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED
This article was originally published in The Tan Sheet
Executive Summary
SEPRACOR R-ALBUTEROL PHASE II INTERIM RESULTS WILL BE PRESENTED during the Nonprescription and Pulmonary-Allergy Drugs Advisory Committees' Nov. 14-15 meeting on the appropriateness of asthma therapies being available over-the-counter. Sepracor's single-isomer version of albuterol may become the "bronchodilator of choice for asthma therapy in both the Rx and OTC markets," the Marlborough, Mass.-based company speculated in a Nov. 9 press release announcing the issuance of a use patent (5,362,755) for the molecule. The Phase II trial of R-albuterol was initiated in Europe in mild asthmatics. Phase II/III trials are projected to begin in 1995.